Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience

BACKGROUND: Cinacalcet is a calcimimetic approved in adults with primary hyperparathyroidism (PHPT). Few cases reports described its use in pediatric HPT, with challenges related to the risk of hypocalcemia, increased QT interval and drug interactions. In this study, we report the French experience...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardor, Julie, Flammier, Sacha, Salles, Jean-Pierre, Amouroux, Cyril, Castanet, Mireille, Lienhardt, Anne, Martinerie, Laetitia, Damgov, Ivan, Linglart, Agnès, Bacchetta, Justine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449487/
https://www.ncbi.nlm.nih.gov/pubmed/36090548
http://dx.doi.org/10.3389/fped.2022.926986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449487/
https://www.ncbi.nlm.nih.gov/pubmed/36090548
http://dx.doi.org/10.3389/fped.2022.926986

Ejemplares similares